Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

France Predictive Genetic Testing Consumer Wellness Genomics Market

ID: MRFR/LS/50121-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026

France Predictive Genetic Testing and Consumer Wellness Genomics Market Research Report By Test Type (Predictive Testing, Consumer Genomics, Wellness Genomics), By Application (Breast & Ovarian Cancer, Cardiovascular Screening, Diabetic Screening & Monitoring, Colon Cancer, Parkinsonism/Alzheimer’s Disease, Urologic Screening/Prostate Cancer Screening, Orthopedic & Musculoskeletal, Others), and By Setting Type (Proteomic Testing, Metabolic Testing, Genomic Testing) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

France Predictive Genetic Testing Consumer Wellness Genomics Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Million)
  49.     4.1.1 Health Risk Assessment
  50.     4.1.2 Carrier Testing
  51.     4.1.3 Ancestry Testing
  52.     4.1.4 Pharmacogenomics
  53.     4.1.5 Nutrigenomics
  54.   4.2 Healthcare, BY End Use (USD Million)
  55.     4.2.1 Healthcare Providers
  56.     4.2.2 Direct-to-Consumer
  57.     4.2.3 Research Institutions
  58.     4.2.4 Pharmaceutical Companies
  59.   4.3 Healthcare, BY Technology (USD Million)
  60.     4.3.1 Next Generation Sequencing
  61.     4.3.2 Microarray Technology
  62.     4.3.3 Sanger Sequencing
  63.     4.3.4 PCR Technology
  64.   4.4 Healthcare, BY Consumer Demographics (USD Million)
  65.     4.4.1 Age Group
  66.     4.4.2 Gender
  67.     4.4.3 Income Level
  68.     4.4.4 Education Level
  69.   4.5 Healthcare, BY Regulatory Environment (USD Million)
  70.     4.5.1 Data Privacy Regulations
  71.     4.5.2 Testing Standards
  72.     4.5.3 Ethical Guidelines
  73.     4.5.4 Insurance Coverage
  74. 5 SECTION V: COMPETITIVE ANALYSIS
  75.   5.1 Competitive Landscape
  76.     5.1.1 Overview
  77.     5.1.2 Competitive Analysis
  78.     5.1.3 Market share Analysis
  79.     5.1.4 Major Growth Strategy in the Healthcare
  80.     5.1.5 Competitive Benchmarking
  81.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  82.     5.1.7 Key developments and growth strategies
  83.       5.1.7.1 New Product Launch/Service Deployment
  84.       5.1.7.2 Merger & Acquisitions
  85.       5.1.7.3 Joint Ventures
  86.     5.1.8 Major Players Financial Matrix
  87.       5.1.8.1 Sales and Operating Income
  88.       5.1.8.2 Major Players R&D Expenditure. 2023
  89.   5.2 Company Profiles
  90.     5.2.1 23andMe (US)
  91.       5.2.1.1 Financial Overview
  92.       5.2.1.2 Products Offered
  93.       5.2.1.3 Key Developments
  94.       5.2.1.4 SWOT Analysis
  95.       5.2.1.5 Key Strategies
  96.     5.2.2 MyHeritage (IL)
  97.       5.2.2.1 Financial Overview
  98.       5.2.2.2 Products Offered
  99.       5.2.2.3 Key Developments
  100.       5.2.2.4 SWOT Analysis
  101.       5.2.2.5 Key Strategies
  102.     5.2.3 Ancestry (US)
  103.       5.2.3.1 Financial Overview
  104.       5.2.3.2 Products Offered
  105.       5.2.3.3 Key Developments
  106.       5.2.3.4 SWOT Analysis
  107.       5.2.3.5 Key Strategies
  108.     5.2.4 Genetic Health (FR)
  109.       5.2.4.1 Financial Overview
  110.       5.2.4.2 Products Offered
  111.       5.2.4.3 Key Developments
  112.       5.2.4.4 SWOT Analysis
  113.       5.2.4.5 Key Strategies
  114.     5.2.5 DNAfit (GB)
  115.       5.2.5.1 Financial Overview
  116.       5.2.5.2 Products Offered
  117.       5.2.5.3 Key Developments
  118.       5.2.5.4 SWOT Analysis
  119.       5.2.5.5 Key Strategies
  120.     5.2.6 Invitae (US)
  121.       5.2.6.1 Financial Overview
  122.       5.2.6.2 Products Offered
  123.       5.2.6.3 Key Developments
  124.       5.2.6.4 SWOT Analysis
  125.       5.2.6.5 Key Strategies
  126.     5.2.7 Fulgent Genetics (US)
  127.       5.2.7.1 Financial Overview
  128.       5.2.7.2 Products Offered
  129.       5.2.7.3 Key Developments
  130.       5.2.7.4 SWOT Analysis
  131.       5.2.7.5 Key Strategies
  132.     5.2.8 GenoPalate (US)
  133.       5.2.8.1 Financial Overview
  134.       5.2.8.2 Products Offered
  135.       5.2.8.3 Key Developments
  136.       5.2.8.4 SWOT Analysis
  137.       5.2.8.5 Key Strategies
  138.     5.2.9 GenePlanet (SI)
  139.       5.2.9.1 Financial Overview
  140.       5.2.9.2 Products Offered
  141.       5.2.9.3 Key Developments
  142.       5.2.9.4 SWOT Analysis
  143.       5.2.9.5 Key Strategies
  144.   5.3 Appendix
  145.     5.3.1 References
  146.     5.3.2 Related Reports
  147. 6 LIST OF FIGURES
  148.   6.1 MARKET SYNOPSIS
  149.   6.2 FRANCE MARKET ANALYSIS BY APPLICATION
  150.   6.3 FRANCE MARKET ANALYSIS BY END USE
  151.   6.4 FRANCE MARKET ANALYSIS BY TECHNOLOGY
  152.   6.5 FRANCE MARKET ANALYSIS BY CONSUMER DEMOGRAPHICS
  153.   6.6 FRANCE MARKET ANALYSIS BY REGULATORY ENVIRONMENT
  154.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  155.   6.8 RESEARCH PROCESS OF MRFR
  156.   6.9 DRO ANALYSIS OF HEALTHCARE
  157.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  158.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  159.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  160.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  161.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
  162.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  163.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
  164.   6.17 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  165.   6.18 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
  166.   6.19 HEALTHCARE, BY CONSUMER DEMOGRAPHICS, 2024 (% SHARE)
  167.   6.20 HEALTHCARE, BY CONSUMER DEMOGRAPHICS, 2024 TO 2035 (USD Million)
  168.   6.21 HEALTHCARE, BY REGULATORY ENVIRONMENT, 2024 (% SHARE)
  169.   6.22 HEALTHCARE, BY REGULATORY ENVIRONMENT, 2024 TO 2035 (USD Million)
  170.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  171. 7 LIST OF TABLES
  172.   7.1 LIST OF ASSUMPTIONS
  173.     7.1.1
  174.   7.2 France MARKET SIZE ESTIMATES; FORECAST
  175.     7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  176.     7.2.2 BY END USE, 2026-2035 (USD Million)
  177.     7.2.3 BY TECHNOLOGY, 2026-2035 (USD Million)
  178.     7.2.4 BY CONSUMER DEMOGRAPHICS, 2026-2035 (USD Million)
  179.     7.2.5 BY REGULATORY ENVIRONMENT, 2026-2035 (USD Million)
  180.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  181.     7.3.1
  182.   7.4 ACQUISITION/PARTNERSHIP
  183.     7.4.1

France Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

  • Health Risk Assessment
  • Carrier Testing
  • Ancestry Testing
  • Pharmacogenomics
  • Nutrigenomics

Healthcare By End Use (USD Million, 2026-2035)

  • Healthcare Providers
  • Direct-to-Consumer
  • Research Institutions
  • Pharmaceutical Companies

Healthcare By Technology (USD Million, 2026-2035)

  • Next Generation Sequencing
  • Microarray Technology
  • Sanger Sequencing
  • PCR Technology

Healthcare By Consumer Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Income Level
  • Education Level

Healthcare By Regulatory Environment (USD Million, 2026-2035)

  • Data Privacy Regulations
  • Testing Standards
  • Ethical Guidelines
  • Insurance Coverage

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓